Novo Nordisk A/S
UBT251
Overweight
Countdown
191days
Phase 2 readout · Jan 14, 2027
What's at stake
Phase 2 trial results for UBT251 in Overweight are due Jan 14, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07395687: Phase 2 trial, sponsor Novo Nordisk A/S, drug UBT251. Primary completion date 2027-01-14 (estimated).”